| [July 23, 2014] |
 |
Research and Markets: Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/sddtlp/top_25)
has announced the addition of the "Top
25 Pharmaceutical Company Pipeline Analysis and Sales Projections to
2023" report to their offering.
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to
2023 takes a considered look at the pharmaceutical industry, including
the late-term pipeline of major companies. This report provides
long-term company sales forecasts which are based on 2013 market
conditions.
For each company, the report provides:
-
Revenues
-
R&D Spending 2007-2013
-
Geographic Breakout of Revenues
-
Performance of Specific Products
-
Performance by Drug Category
-
Late-Stge Pipeline
-
Projections of Revenues to 2023
In addition to specific company data and factors, there are a number of
macroeconomic concerns affecting sales such as aging populations,
incidence of disease, unmet medical needs, government activities, and
more. The pharmaceutical market as a whole has witnessed a number of
significant changes in recent years, providing both setbacks and new
opportunities. The number of blockbuster pharmaceuticals reaching patent
and exclusivity expiration status and vulnerable to generic competition
has changed the landscape of the market for many manufacturers. The
growing interest in biotechnology development has transitioned an
industry once focused on chemical-based therapies to biologic therapies
and produced exceptional changes in many areas of medical treatment over
the last two decades.
The companies included in the study are:
-
Pfizer, inc.
-
Novartis AG
-
Roche ltd.
-
Merck & Co., inc.
-
Sanofi
-
Glaxosmithkline PLC
-
Johnson & johnson
-
Astra Zeneca plc
-
Eli Lilly and Company
-
Abbvie, inc.
-
Teva Pharmaceutical Industries, Ltd.
-
Amgen, inc.
-
Bristol-myers Squibb Company
-
Takeda Pharmaceutical co., LTD
-
Bayer AG
-
Novo nordisk
-
Boehringer Ingelheim gmbh
-
Daiichi Sankyo
-
Astellas
-
Gilead Sciences
-
Otsuka Pharmaceutical
-
Merck KGAA
-
Actavis
-
Mylan
-
Baxter international
For more information visit http://www.researchandmarkets.com/research/sddtlp/top_25
[ Back To TMCnet.com's Homepage ]
|
